CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect Conference
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) announced that CEO John Climaco will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available via a video webcast starting January 10 at 7:00 AM ET. CNS Pharmaceuticals focuses on developing innovative treatments for brain and CNS cancers, including the lead drug candidate Berubicin, which targets glioblastoma multiforme.
- None.
- None.
HOUSTON, Jan. 7, 2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals, will present at the virtual H.C. Wainwright BioConnect Conference taking place January 10-13, 2022.
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, January 10, 2022, at 7:00 AM ET for those registered for the event and will be available on the Events page in the Investors section of the Company's website (www.cnspharma.com). The webcast replay will be archived for 90 days following the event.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and connect with the Company on Twitter, Facebook, and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-hc-wainwright-bioconnect-conference-301456183.html
SOURCE CNS Pharmaceuticals, Inc.
FAQ
What is CNS Pharmaceuticals presenting at the BioConnect Conference?
When is the H.C. Wainwright BioConnect Conference?
How can I view the CNS Pharmaceuticals presentation?
What is the focus of CNS Pharmaceuticals' drug candidates?
What is Berubicin and its significance?
